Join us for the latest Behind the Science discussion, featuring an article published in JACC's May 12 focus issue on hypertension. Adith Arun, MD, joins author William B. White, MD, as they discuss a phase 2 randomized trial of the NPR1 agonist XXB750 in patients with resistant hypertension. The interview highlights the study, a randomized, double-blind, placebo-controlled trial of 4 doses of XXB750, administered once-monthly by subcutaneous injection in 189 patients with resistant hypertension. Dose-related changes in cyclic GMP were observed, supporting target engagement of XXB750 at the NPR-1 receptor. However, there was no dose-response pattern observed with respect to change from baseline in 24-hour systolic BP after 12 weeks; none of the doses of XXB750 had a greater BP lowering effect than placebo. #jacc #jaccjournals #behindthescience